This article is more than 5 years old. Information may no longer be current.

Merck launches glaucoma drug in two European markets

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WHITEHOUSE STATION, N.J. — Merck & Co. has launched tafluprost in the United Kingdom and Spain and expects to launch the drug in other markets pending the receipt of additional regulatory approvals, the company announced in a press release.

Saflutan (tafluprost) is a preservative-free prostaglandin analogue that has received marketing approval in several European and Nordic countries for reducing IOP among patients with primary open-angle glaucoma and ocular hypertension.

The drug is currently in phase 3 clinical development in the United States.

Under the terms of a worldwide licensing agreement Merck entered into with drug developer Santen Pharmaceutical in April, Santen will retain the option to co-promote tafluprost in the U.S. if the drug receives regulatory approval.